Ameriprise Financial Inc. Acquires 25,659 Shares of Gilead Sciences, Inc. $GILD

Key Points

• Ameriprise Financial Inc. increased its stake in Gilead Sciences, owning 1,356,212 shares valued at $151.98 million, representing a 1.9% rise in the 1st quarter.
• Insider selling has occurred at Gilead, with Director Jeffrey Bluestone selling 5,000 shares and CFO Andrew D. Dickinson selling 2,500 shares, indicating a decrease in their holdings, along with a total insider sale of 82,000 shares worth approximately $9.34 million.
• Gilead's latest earnings report showed $2.01 earnings per share, exceeding expectations, with a revenue of $7.08 billion, reflecting a 1.4% increase year-over-year.

Ameriprise Financial Inc. boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,356,212 shares of the biopharmaceutical company's stock after acquiring an additional 25,659 shares during the quarter. Ameriprise Financial Inc. owned 0.11% of Gilead Sciences worth $151,976,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of GILD. Smallwood Wealth Investment Management LLC purchased a new position in Gilead Sciences during the first quarter worth approximately $25,000. Goodman Advisory Group LLC purchased a new stake in Gilead Sciences during the 1st quarter worth about $29,000. Colonial Trust Advisors boosted its position in shares of Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 213 shares in the last quarter. Core Alternative Capital boosted its position in shares of Gilead Sciences by 370.8% during the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after acquiring an additional 241 shares in the last quarter. Finally, IMA Advisory Services Inc. acquired a new position in shares of Gilead Sciences during the 1st quarter worth about $39,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Gilead Sciences Trading Down 1.2%

Shares of Gilead Sciences stock traded down $1.38 during trading hours on Thursday, reaching $112.54. 2,021,832 shares of the company's stock were exchanged, compared to its average volume of 8,179,303. Gilead Sciences, Inc. has a 52-week low of $77.74 and a 52-week high of $121.83. The firm has a market capitalization of $139.64 billion, a price-to-earnings ratio of 22.40, a price-to-earnings-growth ratio of 0.70 and a beta of 0.33. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The company has a fifty day moving average of $112.83 and a 200-day moving average of $109.35.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. During the same period in the prior year, the firm earned $2.01 EPS. The firm's quarterly revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Monday, September 15th. Gilead Sciences's dividend payout ratio is 62.95%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the company's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $109.74, for a total value of $548,700.00. Following the transaction, the director owned 8,920 shares of the company's stock, valued at approximately $978,880.80. This represents a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the sale, the insider directly owned 114,168 shares in the company, valued at approximately $13,532,333.04. This trade represents a 19.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 82,000 shares of company stock valued at $9,339,230. 0.27% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms have recently issued reports on GILD. Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective for the company in a research report on Friday, July 25th. UBS Group upped their price objective on Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research report on Friday, August 8th. Royal Bank Of Canada upped their target price on Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a research report on Friday, August 8th. Daiwa Capital Markets raised Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 target price for the company in a research report on Tuesday, August 19th. Finally, Daiwa America raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Three research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat, Gilead Sciences currently has a consensus rating of "Moderate Buy" and an average price target of $115.39.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.